XOMA Royalty Corporation (NASDAQ:XOMA - Get Free Report) shares crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $27.41 and traded as high as $39.45. XOMA Royalty shares last traded at $36.61, with a volume of 53,962 shares changing hands.
Analysts Set New Price Targets
XOMA has been the subject of a number of recent analyst reports. Zacks Research raised shares of XOMA Royalty from a "hold" rating to a "strong-buy" rating in a report on Wednesday, September 10th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of XOMA Royalty in a research report on Saturday, September 27th. Finally, Wall Street Zen raised XOMA Royalty from a "hold" rating to a "buy" rating in a report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, XOMA Royalty presently has an average rating of "Moderate Buy" and a consensus target price of $69.50.
View Our Latest Research Report on XOMA
XOMA Royalty Price Performance
The company has a market cap of $442.61 million, a P/E ratio of -23.62 and a beta of 1.02. The company's 50-day moving average price is $33.46 and its two-hundred day moving average price is $27.41. The company has a current ratio of 4.88, a quick ratio of 4.88 and a debt-to-equity ratio of 1.41.
XOMA Royalty (NASDAQ:XOMA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The biotechnology company reported $0.48 EPS for the quarter, topping the consensus estimate of ($0.12) by $0.60. The business had revenue of $13.13 million for the quarter, compared to analysts' expectations of $9.39 million. XOMA Royalty had a negative net margin of 27.57% and a positive return on equity of 2.63%. As a group, sell-side analysts expect that XOMA Royalty Corporation will post -1.41 earnings per share for the current year.
Insider Buying and Selling at XOMA Royalty
In other news, CFO Thomas M. Burns sold 4,330 shares of the business's stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $35.99, for a total value of $155,836.70. Following the completion of the sale, the chief financial officer directly owned 30,079 shares in the company, valued at approximately $1,082,543.21. The trade was a 12.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 7.20% of the company's stock.
Institutional Trading of XOMA Royalty
Institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its holdings in shares of XOMA Royalty by 1,063.8% during the first quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 1,585 shares during the period. Tower Research Capital LLC TRC grew its position in shares of XOMA Royalty by 203.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company's stock valued at $57,000 after buying an additional 1,523 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of XOMA Royalty by 13.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company's stock valued at $112,000 after buying an additional 543 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in XOMA Royalty during the second quarter worth about $116,000. Finally, Deutsche Bank AG lifted its holdings in XOMA Royalty by 5,087.9% in the first quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company's stock worth $128,000 after acquiring an additional 6,309 shares during the last quarter. Institutional investors own 95.92% of the company's stock.
XOMA Royalty Company Profile
(
Get Free Report)
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider XOMA Royalty, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XOMA Royalty wasn't on the list.
While XOMA Royalty currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
